96721-87-8

Basic information

• Product Name: 5-(4-aMinophenyl)pyridin-2-aMine
• Synonyms: 5-(4-aMinophenyl)pyridin-2-aMine
• CAS NO: 96721-87-8
• Molecular Formula: C₁₁H₁₁N₃
• Molecular Weight: 185
• Mol File: 96721-87-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-(4-aMinophenyl)pyridin-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-aMinophenyl)pyridin-2-aMine(96721-87-8)
• EPA Substance Registry System: 5-(4-aMinophenyl)pyridin-2-aMine(96721-87-8)

Safety Data

• Hazardous Substances Data: 96721-87-8(Hazardous Substances Data)

Usage

Structure

Consists of a pyridine ring with an amino group at the 2 position and a phenyl ring with an amino group at the 4 position

Uses

Commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals, intermediate in the production of dyes, pigments, and other organic compounds

Properties

Valuable and versatile compound in organic synthesis, due to its chemical structure and properties

Upstream product

• 380430-49-9 [4-(tert-butoxycarbonylamino)phenyl]boronic acid 
• 1072-97-5 5-bromo-2-pyridylamine 
• 766-11-0 5-bromo-2-fluoropyridine 
• 54773-18-1 (E)-2-(phenyldiazenyl)pyridine 
• 7647-01-0 hydrogenchloride 
• 101451-19-8 1-(pyridin-2-yl)-2-phenylhydrazine 

Downstream Products

• 108774-89-6 5-(4-benzylidenamino-phenyl)-[2]pyridylamine 
• 103207-43-8 5-(4-salicylidenamino-phenyl)-[2]pyridylamine 
• 103644-92-4 2-salicylidenamino-5-(4-salicylidenamino-phenyl)-pyridine 
• 101891-47-8 5-[4-(4-dimethylamino-phenylazo)-phenyl]-[2]pyridylamine 
• 1267849-52-4 1-[4-(6-aminopyridin-3-yl)-phenyl]-3-(5-tert-butyl-isoxazol-3-yl)urea 
• 1454771-63-1 C₂₆H₂₈N₆O 

Relevant articles and documents

Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors

Based on a putative binding mode of quizartinib (AC220, 1), a potent FMS-like tyrosine kinase 3 (FLT3) inhibitor in Phase III clinical development, we have designed de novo a simpler aminopyridine-based hinge binding motif. Further optimization focusing on maximizing in vivo efficacy and minimizing CYP3A4 time-dependent inhibition resulted in a highly efficacious compound (6s) in tumor xenograft model for further preclinical development.